Read about the encouraging results at:
Missing Millions – Part 2
Calling all ME patients, allies, family, friends, caregivers, medical providers and researchers: Let’s join together to make this invisible illness visible! Please join us in Morristown, NJ for two hours on September 27th (location TBD).
#MillionsMissing and www.njmecfsa.org is dedicated to the millions of Myalgic Encephalomyelitis (also known as Chronic Fatigue Syndrome) patients missing from their careers, schools, social lives and families due to the debilitating symptoms of the disease. At the same time, millions of dollars are missing from research and clinical education funding that ME should be receiving. And millions of medical providers are missing out on the proper training to diagnosis and help patients manage this illness.
You may also RSVP and follow updates here: https://www.facebook.com/
#MillionsMissing is dedicated to the millions of Myalgic Encephalomyelitis (also known as Chronic Fatigue Syndrome) patients missing from their careers, schools, social lives and families due to the debilitating symptoms of the disease. At the same time, millions of dollars are missing from research and clinical education funding that ME should be receiving. And millions of medical providers are missing out on the proper training to diagnosis and help patients manage this illness.
You may also RSVP here: https://my.meaction.net/
You may also RSVP and follow updates here: https://www.facebook.com/
#MillionsMissing is dedicated to the millions of Myalgic Encephalomyelitis (also known as Chronic Fatigue Syndrome) patients missing from their careers, schools, social lives and families due to the debilitating symptoms of the disease. At the same time, millions of dollars are missing from research and clinical education funding that ME should be receiving. And millions of medical providers are missing out on the proper training to diagnosis and help patients manage this illness.
You may also RSVP here: https://my.meaction.net/
First Approved ME/CFS Treatment in the World
Hemispherx Biopharma Announces Major Breakthrough:
Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic First Product Approved for ME/CFS Indication Anywhere in the World.
Ampligen Approved in Argentina – First in the World 2016-08-23
2016 Membership Renewal
August is Membership Renewal Month
Please support the work of NJME/CFSA. See information at the link below.
Announcing the Winners of #MEAction’s Poetry Contest!
Link includes the 10 poems. http://bit.ly/1UICjb5
i.e. http://www.meaction.net/…/…/meactions-poetry-contest-winners
Medical Scholarship – See Scholarships tab at top of this page
